Drug Profile
Taliglucerase alfa - Pfizer/Protalix Biotherapeutics
Alternative Names: Alfataliglicerase; BioManguinhos alfataliglicerase; Elelyso; Glucocerebrosidase; Oral GCD; prGCD; PRX-112; UplysoLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Protalix Biotherapeutics
- Developer Pfizer; Protalix BioTherapeutics
- Class Glucosidases; Recombinant proteins
- Mechanism of Action Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Gaucher's disease
Most Recent Events
- 27 Feb 2023 Launched for Gaucher's disease in Russia (IV)
- 05 Oct 2022 Launched for Gaucher's disease (In children, In adults) in Canada (IV)
- 01 Dec 2018 Efficacy and adverse events data from an expanded access trial in Gaucher Disease presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)